News and Trends 18 Sep 2017 British Unicorn Gets $40M Boost from Bill & Melinda Gates Foundation The Bill & Melinda Gates Foundation have injected $40M (€33M) into Immunocore to accelerate the development of its immunotherapies for infectious diseases. Investment from the Bill & Melinda Gates Foundation will support the development of Immunocore’s ImmTAV and ImmTAB TCR-based technologies, which help the immune system to target virally and bacterially infected cells, respectively. In particular, […] September 18, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 18 Sep 2017 German Humira Biosimilar for Inflammatory Diseases Cleared for EMA Approval Cyltezo, an adalimumab biosimilar drug by Boehringer Ingelheim, has received the backing to be marketed in Europe. The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended Cyltezo for approval, moving it closer to the market and offering a new treatment for a range of inflammatory diseases. The biosimilar drug of adalimumab (Humira) could treat […] September 18, 2017 - 1 minutemin - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 18 Sep 2017 British Rapid Action Allergy Vaccine Gets Approval for Phase II Trial Allergy Therapeutics’ vaccine against hayfever has received approval to begin a trial to determine its optimal dose. Allergy Therapeutics will begin a Phase II trial of its PQ Grass vaccine for grass pollen-induced allergic rhinitis imminently. A major selling point for PQ Grass is its ultra-short course, which reduces treatment time from 1 year to […] September 18, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 15 Sep 2017 New British Biotech Enters the Clinic with Opioid Alternative for Chronic Pain Levicept’s Phase I study will test their new pain relief candidate’s safety and tolerability in healthy individuals and osteoarthritis patients. Levicept, based in Sandwich, UK, focuses on the development of its pain relief candidate, LEVI-04, a p75 neurotrophin receptor fusion protein (p75NTR-Fc). The Phase I study is the company’s maiden voyage into the clinic, and it will test the […] September 15, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
More News! 14 Sep 2017 Could Using Bacteria’s Own Killing Capacity be a Knockout Blow in the Fight Against Antibiotic Resistance? Scientists in the UK and US have identified how in-fighting between bacteria could provide a new treatment for hospital-acquired infections. Clostridium difficile is a common cause of hospital-acquired infections, which kill almost 4,000 people in Europe each year. Scientists at the University of Sheffield, the University of Glasgow, and California-based biotech AvidBiotics Corp have discovered that C. difficile uses nanomolecular […] September 14, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 13 Sep 2017 Italian Biotech Closes €7M Series B for Stem Cells to Treat Cancer Genenta Science has raised $8M (€7M) in the Series B fundraising round to continue investigating its use of hematopoietic stem cells to treat cancer. Based in Milan, Genenta can add €7M to the €10M secured in Series A of fundraising. Italian, British and Swiss private investors led the investment, and it will allow the biotech to start a second […] September 13, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
More News! 12 Sep 2017 Shire’s Treatment for Chronic Lung Disease in Premature Infants Fast Tracked by FDA The FDA has fast tracked Shire’s candidate for chronic lung disease in extremely premature infants from Phase 2 of clinical development. The FDA has fast tracked Shire’s candidate, SHP607, for the treatment of chronic lung disease based on preclinical data, the results of Phase I and II studies so far, and a lack of treatments […] September 12, 2017 - 1 minutemin - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 12 Sep 2017 Norwegian Biotech Announces Positive Phase I Results for T cell-Stimulating Vaccine PCI Biotech’s T cell-stimulating vaccine enhances the cellular immune response, supporting it as a candidate for use alongside cancer vaccines. PCI Biotech, based in Oslo, Norway, has seen positive initial results in an ongoing Phase I trial for its firmaVacc technology. The trial is being carried out in 110 healthy subjects, and it aims to […] September 12, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 12 Sep 2017 British Biotech Receives €52M Boost To Beat Antimicrobial Resistance with New Antibiotic Summit Therapeutics has been awarded the Barda Contract worth up to $62M (€52M) to continue to the development of a new antibiotic for hospital-acquired infections. Summit Therapeutics, a biopharma company operating in the UK and US, has received the Barda Contract, designed to counter public health emergencies. In this case, the money will help to […] September 12, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
More News! 11 Sep 2017 Could a Protein in Yeast hold the Secret to Escaping Age-Related Diseases? Researchers in Basel, Switzerland have identified a protein in yeast that slows protein synthesis, prolonging their lifespan. Gcn4 is a transcription factor that regulates the expression around 10% of the yeast genome. Nutrient restriction and moderate stress extend lifespan and under these conditions, yeast expresses Gcn4 to regulate protein synthesis. The aim is now to find […] September 11, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 8 Sep 2017 GSK wants in on Adaptimmune’s Adaptable T cell Cancer Treatment GSK has backed Adaptimmune in the development of their adaptable NY-ESO SPEAR T cell cancer therapy, causing an 11% jump in their premarket value. Adaptimmune has received support from GlaxoSmithKline (GSK) for the development of their NY-ESO SPEAR T cell, which will hopefully treat a range of different cancers. The British pharma giant will pay milestones of up to £48M (€52M) […] September 8, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 8 Sep 2017 Spanish Scientists Identify How Gene Activity in Bacteria is Controlled A group in Barcelona has identified DNA close to genes that influence gene activity, which could be used in disease treatment and industrial biotechnology. Sections of DNA, termed ‘control dials‘, regulate transcription, and the amount of gene product produced. Reported in Nature Communications, these findings could help to control dangerous genes during a bacterial infection […] September 8, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email